BAXDELA (delafloxacin) | Your Path Forward

For US Healthcare Professionals Only
Effective Monday, December 13, 2021, the Sample Program for Baxdela will be discontinued. If you have any questions regarding Baxdela, please contact Melinta Medical Information at 1-844-633-6568.

Pathway to ABSSSI Efficacy

Broad Coverage for ABSSSI: gram-positive pathogens, including MRSA, and gram-negative pathogens, including Pseudomonas aeruginosa. See full Indication

See Baxdela ABSSSI Efficacy Results

Explore ABSSSI Safety & Tolerability

See Baxdela ABSSSI Safety Profile

Dosing & Administration

See BAXDELA Dosing & Administration

Next: Introduction

INDICATION & USAGE:

BAXDELA is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following susceptible microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Staphylococcus haemolyticus, Staphylococcus lugdunensis, Streptococcus agalactiae, Streptococcus anginosus group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), Streptococcus pyogenes, and Enterococcus faecalis, Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

For US Healthcare Professionals Only

Melinta Therapeutics, LLC - Unparalleled in passion & purpose

Medical Information
For medical inquiries or to report an adverse event, other safety-related information, or product complaints for a company product, please contact Medical Information. Phone: 1-844-MED-MLNT (1-844-633-6568)
medinfo@melinta.com
www.melintamedicalinformation.com

BAXDELA^® is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria.